Condition
Recurrent Endometrial Undifferentiated Carcinoma
Total Trials
3
Recruiting
0
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
3 of 0 completed with results
Key Signals
3 with results
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Active Not Recruiting2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT03914612Phase 3Active Not Recruiting
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03120624Phase 1Active Not Recruiting
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
NCT00492778Phase 2Unknown
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Showing all 3 trials